Renalytix AI, which is commercializing AI-powered diagnostic tests for kidney disease, raised $74 million by offering 5.5 million ADS equivalents at $13.50, below the as-converted last close of its shares on London's AIM board (RENX). At pricing, the company commands a fully diluted market cap of $490 million.
Renalytix AI plans to list on the Nasdaq under the symbol RNLX. J.P. Morgan and Stifel acted as lead managers on the deal.
